JP2008512344A - Spinal cerebellar degeneration treatment - Google Patents

Abstract

（式中、Ｒはメチル、シアノまたはカルバモイルである）
で示される化合物、その製薬上許容される塩、またはその溶媒和物を有効成分として含有する、脊髄小脳変性症（spinocerebellar ataxia, atrophy, degeneration）もしくは多系統萎縮症の治療剤または運動失調もしくは平衡障害の改善剤。

(Wherein R is methyl, cyano or carbamoyl)
A therapeutic agent or ataxia or equilibrium for spinocerebellar ataxia, atrophy, degeneration, or multiple system atrophy, comprising a compound represented by the above, a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient Disability improving agent.

Description

  The present invention relates to a therapeutic agent for spinocerebellar ataxia or atrophy (degeneration) or multiple system atrophy, or an ataxia or balance disorder improving agent.

  Spinocerebellar degeneration (SCA) includes a neurodegenerative disease having a lesion center in the nucleus or conduction pathway from the cerebellum or brain stem to the spinal cord. A major symptom of SCA is cerebellar or spinal cord ataxia. For example, hereditary olive bridge cerebellar atrophy, hereditary cortical cerebellar atrophy, Machado-Joseph disease, Friedreich's ataxia, hereditary dentate nucleus red nucleus leucocytic atrophy, etc. The hereditary ones are classified into olive bridge cerebellar atrophy, Shy-Drager syndrome, striatal nigra degeneration, cortical cerebellar atrophy, etc., but the cause of the occurrence is unknown. Symptoms and disease progression speeds vary depending on the type of disease, but they are all progressive, eventually becoming a bedridden condition, often associated with pneumonia, death from suffocation, and sudden death. Therefore, investigation of the cause and establishment of an effective treatment method are required.

  Since striatal nigra degeneration, olive bridge cerebellar atrophy and Shy-Drager syndrome are highly common in pathological findings, they may be referred to as multisystem atrophy as a concept encompassing them. Note that the boundary between spinocerebellar degeneration and multiple system atrophy is not clear.

  Thyrotropin-releasing hormone (TRH) is said to be effective for treatment and symptom improvement of spinocerebellar degeneration, and the compounds described in Patent Document 1 and Non-Patent Document 1 are used as therapeutic agents for spinocerebellar degeneration. . Patent Documents 2 to 7 and Non-Patent Document 2 also describe that a compound having a TRH-like action is effective in treating spinocerebellar degeneration or that a TRH derivative has been developed for the treatment of spinocerebellar degeneration. However, the development of a better spinocerebellar degeneration treatment and symptom improvement agent is desired.

  Patent Document 8 discloses a compound that has a central nerve activation effect and can be used for treatment of various symptoms associated with functional decline of dopamine, norepinephrine, and acetylcholine. The structural formulas of the compounds according to the invention are also described.

  Patent Document 9 discloses that the compound according to the present invention is effective in treating Parkinson's disease, and Patent Document 10 has a bioavailability (hereinafter referred to as BA) of 4 to 34 times that of TRH or TRH derivatives. It is disclosed. However, none of them suggests that the compound according to the present invention has a special effect on spinocerebellar degeneration or multiple system atrophy.

JP 61-33197 A JP-A-63-290876 Japanese Patent Laid-Open No. 3-236397 JP-A-6-56886 JP-A-9-157286 JP 59-155346 A JP-A-60-190795 International Patent Application Publication WO 98/08867 Pamphlet International Patent Application Publication WO02 / 17954 Pamphlet International patent application publication WO99 / 53941 pamphlet European Journal of Pharmacology, 1994, page 271, page 357 "Tomorrow's new drugs, drugs for nervous system and sensory organs-2, drugs for central nervous system (Part 2), drugs for peripheral nervous system", edited by Technomic Co., Ltd., July 22, 2004, No. 409 pages

A therapeutic agent for spinocerebellar ataxia or atrophy (degeneration) or multiple system atrophy, or an ataxia or balance disorder improving agent is provided.
The present invention
(1) Formula (I):

(Wherein R is methyl, cyano or carbamoyl)
A therapeutic agent for spinocerebellar degeneration or multiple system atrophy, comprising as an active ingredient a compound represented by: a pharmaceutically acceptable salt thereof, or a solvate thereof,
(2) an ataxia ameliorating agent comprising as an active ingredient a compound represented by the formula (I) described in (1) above, a pharmaceutically acceptable salt thereof, or a solvate thereof;
(3) an agent for improving balance disorder containing, as an active ingredient, the compound represented by the formula (I) described in (1) above, a pharmaceutically acceptable salt thereof, or a solvate thereof,
(4) The therapeutic or ameliorating agent according to (1) above, wherein the spinocerebellar degeneration or multisystem atrophy is Olive Bridge cerebellar atrophy or striatal nigra degeneration,
(5) The therapeutic or ameliorating agent according to any one of (1) to (4), wherein R is methyl,
(6) The therapeutic or ameliorating agent according to (5) above, which is a monohydrate or a trihydrate.
Also,
(7) A compound represented by the formula (I) described in (1) above, a pharmaceutically acceptable salt thereof or a solvate thereof for producing a medicament for the treatment of spinocerebellar degeneration or multiple system atrophy. Use of objects,
And (8) use of a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof as described in (1) above for producing a medicament for improving ataxia,
(9) Use of the compound represented by the formula (I) described in (1) above, a pharmaceutically acceptable salt thereof or a solvate thereof for the manufacture of a medicament for improving balance disorder,
(10) A therapeutically effective amount of the compound represented by the formula (I) described in (1) above, a pharmaceutically acceptable salt thereof or a solvate thereof is administered to a mammal in need thereof. A method for treating spinocerebellar degeneration or multiple system atrophy or a method for improving ataxia or balance disorder is provided.

  The compound according to the present invention has an action to improve ataxia or balance disorder caused by spinocerebellar degeneration or multiple system atrophy, etc., and is a therapeutic agent for spinocerebellar degeneration or multiple system atrophy, or ataxia or balance disorder improvement. It is effective as an agent.

In the present specification, the “solvate” includes, for example, solvates with organic solvents, hydrates and the like. When forming a hydrate, it may be coordinated with an arbitrary number of water molecules, and monohydrate or trihydrate is particularly preferable. The trihydrate suspension is particularly preferable because the particles are difficult to settle and the operability in mass synthesis is high.

  The compounds according to the present invention include pharmaceutically acceptable salts. For example, alkali metals (such as lithium, sodium or potassium), alkaline earth metals (such as magnesium or calcium), ammonium, salts with organic bases and amino acids, or inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid) And salts with organic acids (such as acetic acid, citric acid, maleic acid, fumaric acid, benzenesulfonic acid or p-toluenesulfonic acid). These salts can be formed by a conventional method.

  Further, the compound according to the present invention is not limited to a specific isomer, but includes all possible isomers and racemates.

  The compounds according to the present invention can be obtained by known methods described in Patent Document 8, Patent Document 9 and the like, and further their salts and their solvates (for example, hydrates) are obtained by subjecting them to conventional methods. Can do.

  The compound according to the present invention has an excellent effect of improving ataxia (especially a gait disorder based on coordination disorder and balance disorder) as described in Test Examples described later. Compared with other TRHs or TRH derivatives, the ability to transfer to the brain is improved, and a medicinal effect is shown in small doses. In addition, other TRHs or TRH derivatives are easily metabolized in the brain. However, since the compound according to the present invention has high brain stability, sustained drug efficacy can be expected. Therefore, the dosage can be easily designed, and the dose and the number of doses can be reduced, so that it can be a preferable medicine from the viewpoint of the patient's QOL.

  Such characteristics are unique to the compounds according to the present invention. Patent Document 8 discloses compounds having a structure similar to that of the compound according to the present invention, but the compound according to the present invention exhibits a high ataxia improving effect even when compared with these compounds.

  The compound according to the present invention has a therapeutic action and symptom improving action for all diseases that can be classified as spinocerebellar degeneration or multiple system atrophy. Specific diseases include hereditary olive bridge cerebellar atrophy, hereditary cortical cerebellar atrophy, Friedreich ataxia, Machado-Joseph disease, Ramsay Hunt disease , Hereditary dentate nucleus red nucleus pallidal Louis atrophy and hereditary spastic paraplegia, olive bridge cerebellar atrophy, Shy-Drager syndrome, cortical cerebellar atrophy, striatal nigra degeneration , Marinesco-Sjogren syndrome, alcoholic cortical cerebellar atrophy, paraneoplastic cerebellar degeneration associated with malignant tumors, toxic cerebellar degeneration due to addictive substances, cerebellar degeneration associated with endocrine abnormalities, etc. Is mentioned. Major symptoms include ataxia (gait ataxia, trunk ataxia, limb ataxia), orthostatic hypotension, difficulty urinating, reduced sweating, sleep apnea, dizziness on standing, lower limb tension, nystagmus, Eye movement disorders, pyramidal symptoms, extrapyramidal symptoms (postural adjustment disorder, muscle rigidity, ataxia, tremor), dysphagia, tongue atrophy, posterior symptom, muscle atrophy, muscle weakness, increased deep reflex, Examples include sensory disorder, scoliosis, kyphosis, foot deformity, dysphonia, dementia, mental uplift, and improved rehabilitation.

  In particular, the compounds according to the present invention are effective in improving ataxia and improving balance disorder.

  As used herein, “ataxia” includes spinal ataxia, labyrinth ataxia, cerebral ataxia and cerebellar ataxia, and the compounds according to the present invention are particularly cerebellar ataxia (eg, coordination disorder) And gait ataxia based on balance disorder).

  When the compound according to the present invention is administered to humans for the purpose of treating the above-mentioned diseases or improving symptoms, it can be administered orally as a powder, granule, tablet, capsule, pill, liquid, etc. It can be administered parenterally as an agent, a transdermal absorption agent, an inhalant and the like. In addition, excipients, binders, wetting agents, disintegrants, lubricants and other pharmaceutical additives suitable for the dosage form may be mixed with an effective amount of the present compound as necessary to obtain a pharmaceutical preparation. it can. In the case of an injection, it is sterilized with an appropriate carrier to obtain a preparation. In particular, oral administration using tablets, capsules, easy-to-take intraoral quick disintegrating tablets, jelly preparations, liquids and the like is preferable.

The dose varies depending on the disease state, administration route, patient age, or body weight, but is usually 0.01 to 100 mg / day, preferably 0.1 to 40 mg / day when orally administered to an adult. Yes, most preferably 0.5-20 mg / day. In the case of parenteral administration, the dose varies greatly depending on the administration route, but is usually 0.001 to 10 mg / day, preferably 0.01 to 4 mg / day, and most preferably 0.05 to 2 mg. / Day.

  Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples, but the present invention is not limited thereto.

In the examples, the following abbreviations are used.
BOC: t-butoxycarbonyl p-Ts: p-toluenesulfonyl Me: methyl

Example 1

First step
Preparation of 1-N- [N- (tert-butoxycarbonyl) -3- (thiazol-4-yl) -L-alanyl]-(2R) -2-methylpyrrolidine (3) Reference (J. Am. Chem Soc. 73, 2935 (1951), Chem. Pharm. Bull. 38, 103 (1950)) N- (tert-butoxycarbonyl) -3- (thiazol-4-yl) -L-alanine ( 1, 13.62 g, 50 mmol) and 2 (R) -2-methylpyrrolidine p-toluenesulfonic acid (2, 12.79 g, 50 mmol) synthesized by the method described in the literature (Helv. Chim. Acta, 34, 2202 (1951)) N) N-dicyclohexylcarbodiimide (10.83 g, 52.5 mmol), N-hydroxybenztriazole (2.03 g, 15 mmol) and triethylamine (7.7 ml, 55.2 mmol) were added to a tetrahydrofuran solution (130 ml) of . The deposited precipitate was filtered off, and the filtrate was concentrated to dryness under reduced pressure. The obtained residue was dissolved in ethyl acetate (200 ml) and washed successively with aqueous sodium hydrogen carbonate solution and water. The organic layer was dried over magnesium sulfate and then concentrated to dryness under reduced pressure to obtain the compound (3, 16.45 g, 100%) as an oil.
NMR (CDCl ₃ ): δ _H 8.76 and 8.75 (1 H, each d, J = 2.1Hz, Thia-H-2), 7.08 (1 H, d, J = 2.1Hz, thia-H-5), 5.45 (1 H, m, NH), 3.45-3.64 (1 H, m, Ala-CαH), 4.14 and 3.81 (1 H, each m, Pyr-CαH), 3.51 (1 H, m, pyr-NCH ₂ ) , 3.1-3.4 (3 H, m, Pyr-CH ₂ and Ala-CH ₂ ), 1.39 (9 H, s, BOC), 1.3-2.0 (4 H, m, pyr-CH ₂ ), 1.06 (3 H , d, J = 6Hz, Pyr-Me)

Second step
Preparation of 1-N- [3- (thiazol-4-yl) -L-alanyl]-(2R) -2-methylpyrrolidine di-p-toluenesulfonate (4) Compound (3, 33.77 g, 99.48 mmol ) And p-toluenesulfonic acid hydrate (37.85 g, 199 mmol) were dissolved in ethyl acetate (101 ml) and ice-cooled. A 4 mol / L hydrogen chloride-ethyl acetate solution (125 ml) was added and stirred for 2 hours and 45 minutes, and then the reaction mixture was concentrated to dryness under reduced pressure. Methanol was added to the resulting residue, and the mixture was concentrated to dryness again. Methanol-toluene (1: 1) was added to the residue and concentrated to dryness under reduced pressure to obtain a crystalline residue. The residue was washed with acetone, and the crystals were collected by filtration to obtain the compound (4, 36 g, 62%). The mother liquor was concentrated to dryness under reduced pressure, methanol and toluene were added to the residue, and the mixture was concentrated to dryness. The obtained crystalline residue was washed with acetone to obtain a further compound (4, 10.67 g, 18.4%).
mp 188-189 ℃
[α] _D ²⁴ +2.2 (c, 1.0, MeOH)
IR (KBr) cm ^-1 : 3431, 3125, 3080, 2963, 1667, 1598, 1537, 1497, 1451, 1364, 1229, 1198, 1170, 1123, 1035, 1011.
NMR (CD ₃ OD): δ _H 9.04 and 9.03 (1 H, each d, J = 2.1Hz, Thia-H-2), 7.70 (2 H, m, aromatic H), 7.46 (1 H, d, J = 2.1Hz, thia-H-5), 7.23 (2 H, m, aromatic H), 4.49 and 4.46 (1 H, each d, J = 6.9Hz, Ala-CαH), 4.14 and 3.75 (1 H, each m, Pyr-CαH), 3.51 (1 H, m, pyr-NCH ₂ ), 3.2-3.4 (3 H, m, Pyr-CH ₂ and Ala-CH ₂ ), 2.36 (3 H, s, aromatic Me) , 1.3-2.0 (4 H, m, pyr-CH ₂ ), 1.19 and 1.07 (3 H, each d, J = 6.3Hz, Pyr-Me)
Elemental analysis (C ₁₁ H ₁₇ N ₃ OS 2C ₇ H ₈ O ₃ S)
Calculated: C, 51.44%; H, 5.70%; N, 7.20%; S, 16.48%.
Found: C, 51.36%; H, 5.69%; N, 7.23%; S, 16.31%.

Third process
1- [N-[(4S, 5S)-(5-Methyl-2-oxooxazolidin-4-yl) carbonyl] -3- (thiazol-4-yl) -L-alanyl- (2R) -2-methyl Pyrrolidine trihydrate (I-1)
Third step (1)
Method A (J. Chem. Soc. 1950, 62; Tetrahedron 48; 2507 (1992); Angew. Chem. 101, 1392 (1989)) (4S, 5S) -5-methyl-2- Oxooxazolidin-4-ylcarboxylic acid (5, 1.368 g, 9.43 mmol), compound (4, 5 g, 8.56 mmol) and N-hydroxysuccinimide (217 mg, 1.89 mmol) dissolved in N, N-dimethylformamide (10 ml) Then, tetrahydrofuran (65 ml) was added, and after cooling with ice, triethylamine (2.63 ml, 18.86 mmol) and N, N-dicyclohexylcarbodiimide (2.04 g, 9.89 mmol) were added with stirring and stirred for 30 minutes. After removing the precipitate by filtration, the filtrate was concentrated to dryness under reduced pressure, 100 ml of water was added to 9.95 g of the resulting residue, and the mixture was stirred at room temperature for 1 hour and 30 minutes. The insoluble material was removed by filtration, and the filtrate was concentrated to about half volume under reduced pressure, and a small amount of insoluble material was removed by filtration. Concentrated to 20 g, left in a refrigerator for 3 days, 2.98 g of the precipitated crystals were collected by filtration, washed with cold water, extracted twice with chloroform, dried over magnesium sulfate, and concentrated to dryness under reduced pressure. 5 ml of ethyl acetate was added to 1.05 g of the oily residue and stirred to obtain 136 mg of crystals, which were combined with the crystals obtained above and dissolved in 45 ml of purified water by heating. The filtrate was concentrated under reduced pressure and allowed to stand at room temperature overnight After cooling with ice, the crystals were collected by filtration to obtain the compound (I-1, 2.89 g, 80.3%).
mp 194-196 ℃
[α] _D ²² -2.0 ± 0.4 ゚ (c, 1.008, H ₂ O), [α] ₃₆₅ + 33.1 ± 0.7 ゚ (c, 1.008, H ₂ O)
IR (Nujor) cm ^-1 : 3517, 3342, 3276, 3130, 3092, 3060, 1754, 1682, 1610, 1551, 1465, 1442, 1379, 1235, 1089.
NMR (CD ₃ OD): δ _H 8.97 and 8.96 (total 1 H, d, J = 2.1Hz, Thia-H-2), 7.34 and 7.33 (total 1 H, d, J = 2.1Hz, Thia-H- 5), 5.18 and 5.04 (total 1 H, each t, J = 7.5Hz, Ala-CαH), 4.92 (1 H, dq, J = 6.6 and 8.7Hz, Oxa-H-5), 4.36 and 4.35 (total 1 H, d, J = 8.7Hz, Oxa-H-4), 4.07 and 3.92 (total 1 H, each m, Pyr-Cα-H), 3.78 (1 H, m, Pyr-NCH ₂ ), 3.42 ( 1 H, m, Pyr-NCH ₂ ), 3.22 (2 H, m, Ala-CH ₂ ), 1.5-2.0 (4 H, m, Pyr-CH ₂ ), 1.28 and 1.22 (total 3 H, each d, J = 6.6Hz, Oxa-5-Me), 1.21 and 1.02 (total 3 H, each d, J = 6.6Hz, Pyr-2-Me)
Anal Calcd For C ₁₆ H ₂₂ N ₄ O ₄ S 3H ₂ O
Calculated: C, 45.00%; H, 6.71%; N, 13.33%; S, 7.63%.
Found: C, 45.49%; H, 6.60%; N, 13.58%, S, 7.88%.

Third step (2)
Method B
The compound (I-2, 410 g, 1.119 mol) was dissolved by heating in 6.3 L of purified water, and then concentrated under reduced pressure until the total weight reached 1370 g. The concentrate was left at room temperature overnight. The concentrated solution was cooled for 1 hour under ice cooling, and the precipitated crystals were collected by filtration and washed with cold water to obtain the compound (I-1, 448 g, 95.2%) as colorless crystals. Further, the mother liquor was dissolved by heating again in 300 mL of purified water, and then concentrated under reduced pressure until the total weight became 55 g. The concentrated solution was allowed to stand at room temperature overnight, and the precipitated crystals were collected by filtration to obtain the compound (I-1, 16.3 g, 3.5%) (total 464.3 g, 98.7%).
mp 194-196 ℃
[α] _D ²² -0.9 ± 0.4 ° (c, 1.007, H ₂ O), [α] ₃₆₅ + 35.4 ± 0.8 ° (c, 1.007, H ₂ O)
IR (Nujor) cm ^-1 : 3511, 3348, 3276, 3130, 3093, 3060, 1755, 1739, 1682, 1611, 1551, 1465, 1442, 1379, 1235, 1089.
Elemental analysis (C ₁₆ H ₂₂ N ₄ O ₄ S 3H ₂ O)
Calculated values: C, 45.00%; H, 6.71%; N, 13.33%; S, 7.63%.
Found: C, 45.56%; H, 6.66%; N, 13.43%, S, 7.69%.

Fourth step
1- [N-[(4S, 5S)-(5-Methyl-2-oxooxazolidin-4-yl) carbonyl] -3- (thiazol-4-yl) -L-alanyl- (2R) -2-methyl Pyrrolidine (I-2)
Method A
1- [N-[(4S, 5S)-(5-methyl-2-oxooxazolidin-4-yl) carbonyl] -3- (thiazol-4-yl) -L synthesized by the method described in Patent Document 8 -Alanyl- (2R) -2-methylpyrrolidine monohydrate (4.77 g) was pulverized in a mortar and then dried under reduced pressure (66.5 Pa) at 100 ° C. for 15 hours to give compound (I-2) 4.54 g was obtained.
mp 194.5-196.5 ℃
[α] _D ²⁵ -2.1 ± 0.4 ° (c, 1.004, H ₂ O), [α] ₃₆₅ + 36.8 ± 0.8 ° (c, 1.004, H ₂ O)
Moisture measurement (Karl Fischer method): 0.27%
IR (Nujor) cm ^-1 : 3276, 3180, 3104, 1766, 1654, 1626, 1548, 1517, 1457, 1380, 1235, 1102, 979.
NMR (CD ₃ OD): δ _H 8.97 and 8.96 (total 1 H, d, J 2.1 Hz, Thia-H-2), 7.34 and 7.33 (total 1 H, d, J 2.1 Hz, Thia-H-5) , 5.19 and 5.04 (total 1 H, each t, J 7.5 Hz, Ala-CαH), 4.92 (1 H, dq, J 6.6 and 8.7 Hz, Oxa-H-5), 4.36 and 4.35 (total 1 H, d , J 8.7 Hz, Oxa-H-4), 4.07 and 3.92 (total 1 H, each m, Pyr-Cα-H), 3.78 (1 H, m, Pyr-NCH ₂ ), 3.42 (1 H, m, Pyr-NCH ₂ ), 3.22 (2 H, m, Ala-CH ₂ ), 1.5-2.0 (4 H, m, Pyr-CH ₂ ), 1.28 and 1.22 (total 3 H, each d, J 6.6 Hz, Oxa -5-Me), 1.21 and 1.02 (total 3 H, each d, J 6.6 Hz, Pyr-2-Me).
Elemental analysis (C ₁₆ H ₂₂ N ₄ O ₄ S)
Calculated: C, 52.44%; H, 6.05%; N, 15.29%; S, 8.75%.
Found: C, 52.24%; H, 5.98%; N, 15.27%, S, 8.57%.

Method B compound (I-1, 17.89 g, 47.3 mmol) was pulverized in a mortar and then heat-dried under reduced pressure (66.5 Pa) at 100 ° C. for 14 hours to obtain compound (I-2, 17.31 g).
mp 193-194 ℃
[α] _D ²⁵ -1.9 ± 0.4 ゚ (c, 1.002, H ₂ O), [α] ₃₆₅ + 37.2 ± 0.8 ゚ (c, 1.002, H ₂ O)
Moisture measurement (Karl Fischer method): 0.22%
IR (Nujor) cm ^-1 : 3273, 3180, 3111, 1765, 1685, 1653, 1626, 1549, 1516, 1456, 1346, 1331, 1277, 1240, 1097, 980.
Calculated value (C ₁₆ H ₂₂ N ₄ O ₄ S)
Calculated: C, 52.44%; H, 6.05%; N, 15.29%; S, 8.75%.
Found: C, 52.19%; H, 5.98%; N, 15.42%, S, 8.74%.

Test Example 1 Effect of Improving Ataxia in Rolling Mouse Nagoya Rolling mouse Nagoya, a hereditary ataxia mouse, is known as a model mouse for spinocerebellar degeneration, and many papers have been reported (E. Kurihara, N. Fukuda, S. Narumi, T. Matsuo, S. Saji, and Y. Nagawa, Jpn. Pharmacol., Ther., 13, 49-56 (1985), Y. Mano, K. Matsui, E. Toyoshima, and K Ando, Acta. Neurol. Scand., 73, 352-358 (1986), K. Kinoshita, T. Fujitsuka, M. Yamamura, and Y. Matsuoka, Eur. J. Pharmacol., 274, 65-72 (1995) K. Kinoshita, T. Fukushima, Y, Kodama, J. Sugihara, M. Yamamura, and Y. Matsuoka, Biol. Pharm. Bull., 20, 36-39 (1997)).

The effect of compound (I-1) on ataxia of rolling mouse Nagoya was examined. As the control compounds 1 and 2, the following compounds described in Patent Document 1 and Non-Patent Document 1 were used.

  The ataxia-improving effect was determined by the fall index using an open field. The mouse was placed in the center of an open field (circular open field (diameter 75 cm, 25 fractions)), the number of moving frames and the number of falls for 5 minutes were measured, and the falling index (number of falls / number of moving frames) was determined.

  Each compound was dissolved in physiological saline on the day of the experiment. Compound (I-1) was 1 mg / kg and 3 mg / kg, control compound 1 was 30 mg / kg and 100 mg / kg, control compound 2 was 100 mg / kg and 300 mg / kg. The mice were orally administered using an oral sonde to a weight of kg. In the control group, only physiological saline was orally administered. An administration sample was prepared so that the amount of oral administration solution was 0.2 mL per 20 g of mouse body weight.

  In any mouse, the ataxia-improving effect was determined in the open field 1 hour after administration. The number of cases was 5 or more in any group.

  The results are shown in FIG. 1 (*: p <0.05, **: p <0.01). Compound (I-1) showed an ataxia-improving effect superior to that of the control group at 3 mg / kg. Control compound 1 showed an ataxia-improving effect superior to that of the control group only at 100 mg / kg, and control compound 2 could not recognize the improving action even at 300 mg / kg.

  From the above results, it can be seen that the compound (I-1) exhibits a very excellent ataxia-improving action of 30 times or more compared to the control compound 1 and 100 times or more compared to the control compound 2.

As described in Patent Document 10, the compound according to the present invention has a higher BA as compared with the control compound, but the ataxia-improving effect is higher than that of the control compound. Such an excellent effect does not depend only on BA, and the compound according to the present invention exhibits an excellent effect on ataxia improvement.

Test example 2: Ara-C administration improves ataxia in rats with cerebellar disorders. Ara-C (60 mg / kg, Nippon Shinyaku) is administered subcutaneously to Sprauge-Dawley rats (CLEA Japan) on the second and third days of life The ataxia-improving effect of compound (I-1) and control compounds 1 and 2 at 4 weeks of age was examined.

  The ataxia-improving effect was determined by the fall index using an open field. The rat was placed in the center of an open field (circular open field (diameter 75 cm, 25 fractions)), the number of moving frames and the number of falls for 3 minutes were measured, and the fall index (number of falls / number of moving frames) was determined.

  Each compound was dissolved in physiological saline on the day of administration, Compound (I-1) was 0.1 mg / kg, 0.3 mg / kg, 1 mg / kg and 3 mg / kg, Control Compound 1 was 30 mg / kg and 100 mg / kg, Control compound 2 was orally administered to rats using an oral sonde at 100 mg / kg and 300 mg / kg. In the control group, only physiological saline was orally administered. The administration was repeated once a day for 7 days, and the effect 24 hours after the final administration was examined. An administration sample was prepared so that the amount of oral administration solution was 0.1 mL per 100 g of rat body weight. The number of cases was 5 or more in any group.

  The results are shown in FIG. 2 (**: p <0.01). Compound (I-1) showed an ataxia-improving action superior to that of the control group at 0.3 mg / kg or more. Control compound 1 showed an ataxia-improving effect superior to that of the control group only at 100 mg / kg, and control compound 2 could not recognize the improving effect even at 300 mg / kg.

  From the above results, Control Compound 1 shows the same efficacy as Compound (I-1) at a dose of 1/300, and Control Compound 2 is equivalent to Compound (I-1) at a dose of 1/1000 or less. Was the effectiveness. It can be seen that the compound (I-1) exhibits a very excellent ataxia improving action.

Similar to the results of Test Example 1, this result shows that the excellent ataxia-improving action of the compound according to the present invention does not depend only on BA.

Test Example 3 Ataxia Improvement Effect in Rolling Mouse Nagoya For the compound described in Patent Document 8 (I-3: R = CN, I-4: R = CONH ₂ ) and Control Compound 2, the effect on ataxia in rolling mouse Nagoya It was investigated.

  The ataxia-improving effect was determined by the fall index using an open field. Place the mouse in the center of the open field (100cm square flat field divided into 25 pieces of 20cm square), measure the number of moving frames and the number of falls for 10 minutes, and the fall index (number of falls / number of moves) )

  Each compound is dissolved in physiological saline on the day of the experiment, and orally administered to mice using an oral sonde so that compounds (I-3) and (I-4) are 10 mg / kg, and control compound 2 is 100 mg / kg. did. An administration sample was prepared so that the amount of oral administration solution was 0.2 mL per 20 g of mouse body weight.

  In any mouse, the fall index was measured in the open field, and the compound was orally administered immediately after that. One hour after administration, the fall index was measured again in the open field, and the ataxia improving effect was determined. The number of cases was 5 or more in any group.

The results are shown in FIG. 3 (*: p <0.05, **: p <0.01). Compounds (I-3) and (I-4) showed a strong ataxia-improving effect by oral administration, and control compound 2 showed a weak improving effect.
From the above results, it was found that the compounds (I-3) and (I-4) exhibited an excellent ataxia improving action.

Formulation Example 1
A granule containing the following ingredients is produced.

Ingredient Compound represented by formula (I) 10mg
Lactose 700mg
Corn starch 274mg
HPC-L 16mg
1000mg
The compound of formula (I) and lactose are passed through a 60 mesh sieve. Pass cornstarch through a 120 mesh sieve. These are mixed in a V-type mixer. Add HPC-L (low-viscosity hydroxypropylcellulose) aqueous solution to the powder mixture, knead, granulate (extruded granulation pore size 0.5-1mm), and dry. The obtained dried granules are combed with a vibrating sieve (12/60 mesh) to obtain granules.

Formulation Example 2
A capsule filling granule containing the following ingredients is produced.

Ingredient Compound represented by formula (I) 15mg
Lactose 90mg
Cornstarch 42mg
HPC-L 3mg
150mg
The compound of formula (I), lactose, is passed through a 60 mesh sieve. Pass cornstarch through a 120 mesh sieve. These are mixed, and the HPC-L solution is added to the mixed powder to knead, granulate and dry. After sizing the obtained dry granules, 150 mg thereof is filled into No. 4 hard gelatin capsules.

Formulation Example 3
A tablet containing the following ingredients is produced.

Ingredient Compound represented by formula (I) 10mg
Lactose 90mg
Microcrystalline cellulose 30mg
CMC-Na 15mg
Magnesium stearate 5mg
150mg
The compound represented by the formula (I), lactose, microcrystalline cellulose and CMC-Na (carboxymethylcellulose sodium salt) are passed through a 60 mesh sieve and mixed. The mixed powder is mixed with magnesium stearate to obtain a mixed powder for tableting. This mixed powder is directly hit to obtain a 150 mg tablet.

  The compound according to the present invention can be an effective medicament as a therapeutic agent for spinocerebellar degeneration or multiple system atrophy, or an ataxia or balance disorder improving agent.

It is a graph which shows the ataxia (equilibrium disorder) improvement effect in rolling mouse | mouth Nagoya of a compound (I-1). It is a graph which shows the ataxia (equilibrium disorder) improvement effect in the cerebellar disorder rat by Ara-C administration of a compound (I-1). It is a graph which shows the ataxia (equilibrium disorder) improvement effect in rolling mouse | mouth Nagoya of compound (I-3) and (I-4).

Claims (10)

Formula (I):

(Wherein R is methyl, cyano or carbamoyl)
Or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient. A therapeutic agent for spinocerebellar degeneration or multiple system atrophy. An ataxia ameliorating agent comprising a compound represented by the formula (I) according to claim 1, a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient. An agent for improving equilibrium disorder comprising a compound represented by the formula (I) according to claim 1, a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient. The therapeutic agent or ameliorating agent according to claim 1, wherein the spinocerebellar degeneration or multisystem atrophy is Olive Bridge cerebellar atrophy or striatal nigra degeneration. The therapeutic agent or ameliorating agent according to any one of claims 1 to 4, wherein R is methyl. The therapeutic agent or ameliorating agent according to claim 5, which is a monohydrate or a trihydrate. A compound represented by formula (I) according to claim 1, for producing a medicament for the treatment of spinocerebellar degeneration or multiple system atrophy, a pharmaceutically acceptable salt thereof, or a solvate thereof Use of. Use of a compound represented by formula (I) according to claim 1, a pharmaceutically acceptable salt thereof or a solvate thereof for the manufacture of a medicament for improving ataxia. Use of a compound of formula (I) according to claim 1, a pharmaceutically acceptable salt thereof or a solvate thereof for the manufacture of a medicament for improving balance disorder. A therapeutically effective amount of a compound represented by formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof is administered to a mammal in need thereof. A method for treating spinocerebellar degeneration or multiple system atrophy, or a method for improving ataxia or balance disorder.

Images